Virotherapy for cancer: Current status, hurdles, and future directions

Cancer Gene Therapy

Volumn 9, Issue 12, 2002, Pages 959-960

  Kirn, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; INTERLEUKIN 2; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; DRUG SELECTIVITY; EDITORIAL; GENE DELETION; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; MEASLES VIRUS; METASTASIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REOVIRUS; RNA VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIROTHERAPHY; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; NEOPLASM; VIROLOGY; VIRUS;

GENE THERAPY; HUMANS; NEOPLASMS; VIRUSES;

EID: 0036905080     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700554     Document Type: Editorial

References (11)

1. Russell SJ. RNA Viruses as Virotherapy Agents.
2. Varghese S, Rabkin S. Oncolytic Herpes Simplex Virus Vectors for Cancer Virotherapy.
3. Reid T, Warren R, Kim D. Intravascular Adenoviral Agents in Cancer Patients: Lessons from Clinical Trials.
4. Nemunaitis J, Edelman J. Selectively Replicating Viral Vectors.
5. Bartlett D. Poxvirus for Virotherapy: Translational Research.
6. Mastrangelo MJ, Lattime EC. Virotherapy Clinical Trials for Regional Disease: In Situ Immune Modulation using Recombinant Poxvirus Vectors.
7. Green NK, Seymour LW. Adenoviral Vectors: Systemic Delivery and Tumor Targeting.
8. Ochsenbein AF. Principals of Tumor Immunosurveillance and Implications for Immunotherapy.
9. Hermiston T. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J Clin Invest. 2000;105:1169-1172.
10. Wisher MH. Biosafety and Product Release Testing Issues Relevant to Replication-competent Oncolytic Viruses.
11. Vile R, Ando D, Kim D. Scientific, Regulatory, and Biosafety Hurdles for Virotherapy Agents.